Endocrine > Thyroid > I-131 for cancer

J Nucl Med 1994 Nov;35(11):1797-801

Iodine-131 in breast milk following therapy for thyroid carcinoma.

Robinson PS, Barker P, Campbell A, Henson P, Surveyor I, Young PR.

This study evaluates breast milk secretion of 131I following therapeutic administration of 4000 MBq of 131I-iodide during lactation. METHODS: Breast milk 131I activity concentration was measured over a 32-day period. Dosimetry calculations were undertaken to estimate the period for discontinuation of breast feeding and the equivalent dose to the breasts. RESULTS: To achieve an infant effective dose < 1 mSv and an infant thyroid dose < 10 mSv, breast feeding would need to be discontinued for at least 52 days. The estimated equivalent dose to the breasts was 1.6 Gy. CONCLUSION: It is suggested that 131I-iodide administration is not undertaken during lactation and that breast feeding is discontinued several days prior to administration.

Latest in Endocrine
Page 1 of 8
Next Page